(Total Views: 166)
Posted On: 08/26/2020 1:19:06 PM
Post# of 15417
$QBIO Huge News ~ Q BioMed Announces Initiation of GMP Production of Novel COVID-19 Therapeutic for Clinical Trial Program
COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government
Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others
NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical grade therapeutic intended to treat complications caused by COVID-19. The Phase 1 clinical trial is slated to begin patient enrollment in February 2021.
The accelerated development of this novel virus-agnostic and host-directed therapeutic is being supported in part by funding from the Canadian and German governments under various R&D incentive and COVID-19 response initiative
https://finance.yahoo.com/news/q-biomed-annou...00905.html
COVID-19 clinical trial planned for Q1 2021 supported by Canadian Government
Proof of concept would validate platform for multiple indications and therapeutic alternatives in infectious diseases and others
NEW YORK, Aug. 26, 2020 /PRNewswire/ -- Q BioMed Inc. (OTCQB: QBIO), a commercial stage biotech company, announced today that with its technology partner, Mannin Research, a GMP production contract has been initiated for MAN-19, a clinical grade therapeutic intended to treat complications caused by COVID-19. The Phase 1 clinical trial is slated to begin patient enrollment in February 2021.
The accelerated development of this novel virus-agnostic and host-directed therapeutic is being supported in part by funding from the Canadian and German governments under various R&D incentive and COVID-19 response initiative
https://finance.yahoo.com/news/q-biomed-annou...00905.html
(0)
(0)
